SB 1484 requires Oklahoma medical examiners to conduct standardized investigations for sudden infant or young deaths (including SIDS, SUID, SDY, and SADS), mandating autopsies when needed, review of medical records, and documentation of recent immunizations. It requires medical examiners to notify parents or legal guardians before investigations begin and grants them the right to refuse parts of the process unless a crime is suspected. The bill expands mandatory investigations to cover all sudden unexplained deaths in children under 20, requiring reporting to a national CDC/NIH registry and sharing findings with the State Department of Health. This directly affects medical examiners, parents/guardians of deceased children, and state health authorities through new procedural requirements.
SB 1567 modifies Oklahoma's rules for Advanced Practice Registered Nurses (APRNs) by allowing supervising physicians to charge reasonable fees for oversight services, requiring these fees to be disclosed in written agreements and based on fair market value. The bill prohibits the Oklahoma Board of Nursing from imposing fees for maintaining supervision agreements or related administrative tasks. It also mandates that supervision agreements include specific details like fee structures, scope of practice, emergency plans, and alternate physician designations. This directly affects APRNs who rely on physician supervision and supervising physicians, streamlining oversight requirements while ensuring transparency in fee arrangements.
SB 1500 requires pharmacy benefits managers (PBMs) and other payors to pay pharmacies within 30 days for "clean claims" (properly submitted claims without issues). It prohibits PBMs from conditioning payments on post-transaction reconciliations or shifting payment delays to pharmacies, and mandates transparent accounting for payments. The bill also authorizes Oklahoma’s Attorney General to impose fines for violations and voids contracts that violate these rules. These changes directly affect pharmacies (as providers) and PBMs/insurers (as payors) by standardizing payment timelines and reducing financial risk for pharmacies.
SB 444 updates Oklahoma's rules for disposing of expired, unused, or abandoned controlled substances (like prescription medications). It allows regular people (ultimate users) to safely dispose of their own medications without registration, permits hospice programs to handle medications from deceased patients under federal rules, and removes previous restrictions on disposal methods. All disposal must follow federal guidelines (21 C.F.R. Part 1317), require specific forms for hospice cases, and be documented for state/federal review. The law takes effect November 1, 2025.
SB 933 requires Oklahoma hospitals and ambulatory surgical centers to adopt policies using surgical smoke evacuation systems during procedures likely to generate surgical smoke. These systems must capture smoke at the source before it reaches staff or patients' eyes or lungs. The bill defines "surgical smoke" as gaseous by-products like plume or bio-aerosols produced during energy-based surgical procedures. The policy must be implemented by November 1, 2025, to prevent exposure to this airborne hazard.
HB 1168 makes it a felony to knowingly deliver or possess abortion-inducing drugs (like misoprostol or methotrexate) with the intent of causing an abortion, punishable by up to $100,000 in fines or 10 years in prison. It directly affects individuals who provide such drugs for non-exceptional purposes, including off-label use for abortion. Key exceptions include pharmacists, manufacturers, and distributors acting within lawful medical practices, as well as preventive contraception used as directed by manufacturers. The law does not restrict treatment for ectopic pregnancies, miscarriages, or medical uses of drugs like chemotherapy.
SB 1255 requires Oklahoma's Department of Corrections medical director to certify qualifying medical conditions and request the Pardon and Parole Board to place eligible inmates on a special docket for compassionate parole consideration. It directly affects inmates with specific terminal or debilitating conditions like dementia, cancer, HIV/AIDS, or conditions causing near-death (six-month life expectancy), or those unable to perform basic self-care. The bill bypasses the standard two-step parole hearing process for these inmates and mandates that at least three Board members must concur to consider medical parole. The Board must document concurrence in meeting minutes, and parolees may face revocation if their medical condition poses public safety risks.
HB 3143 extends Oklahoma's moratorium on new medical marijuana business licenses (dispensaries, processors, growers) from August 1, 2026, to August 1, 2028. It requires existing license holders to get written approval from the Oklahoma Medical Marijuana Authority before transferring ownership, including submitting documentation to the Oklahoma State Bureau of Narcotics. Transfers must follow a 15-business-day timeline for license and registration changes, and applicants cannot submit transfer requests if disciplinary actions are pending. The bill also mandates that businesses provide a full inventory of all medical marijuana products during ownership changes and prohibits transfers without approval, with a 30-day window for pending applications to comply with new rules.
This bill requires Oklahoma hospitals to provide patients experiencing fetal death or miscarriage with a form explaining how to request official certificates (fetal death or stillbirth birth certificates) before discharge. Hospitals must also verbally inform patients about these certificate options. The State Department of Health must create and publish this standardized form online, including clear instructions and contact details for vital records. The law takes effect November 1, 2026, directly affecting hospitals and patients in Oklahoma facing these medical circumstances.
SB 2007 requires pharmacy benefit managers (PBMs) in Oklahoma to pay administrative fees to pharmacies when they adjust reimbursement rates for the same drug within 30 days after a successful appeal. Specifically, if a PBM increases reimbursement based on an appeal but then lowers it again for the same drug within 30 days, the PBM must pay $100 immediately, escalating to $500 after 90 days or $1,000 after 180 days if unpaid. The bill directly affects pharmacies and PBMs by mandating these fee payments for disputed reimbursements, ensuring providers aren’t financially penalized for legitimate appeal outcomes. It also includes other provisions like weekly MAC price updates and requirements for PBMs to provide clear documentation during reimbursement disputes. The law takes effect November 1, 2026.
